ArticleCureus2023
Epipharynegal Abrasive Therapy Downregulates the Number of Epipharyngeal Abrasive CD4 Cells With Symptomatic Recovery.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 7 citations in OpenAlex.
- Association Between Granular Changes on Epipharyngeal Endoscopy and Allergen Sensitization in Chronic Epipharyngitis.Reports (MDPI) · 2026Article
- Article
- Th17/Treg Imbalance Reveals Local-Systemic Immune Dissociation in Nasopharyngeal Inflammation and Its Association with Endoscopic Severity.Medicina (Kaunas, Lithuania) · 2026Article
- Article
- Article
- Review
- Retracted: Chronic Epipharyngitis Treated with Epipharyngeal Abrasion Therapy: Symptoms, Diagnosis, Pathogenesis, and Treatment Outcomes.JMA journal · 2025Review
- Article
- Review
- A Comparative Review of the Terms Epipharyngitis and Nasopharyngitis in Medical Literature.Cureus · 2024Review
- Autonomic Stimulation Action of EAT (Epipharyngeal Abrasive Therapy) on Chronic Epipharyngitis.Cureus · 2024Review
- A Case Report of Chronic Epipharyngitis With Chronic Fatigue Treated With Epipharyngeal Abrasive Therapy (EAT).Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn this study, the author focused on CD4 and CD8 profiles in epipharyngeal abrasive cells in patients with chronic epipharyngitis and investigated how the profiles differ from those in normal healthy subjects and how epipharyngeal abrasive therapy (EAT) influences these profiles.
methodsThis study included 18 patients (one male and 17 females, median age: 46 (30.0-56.5) years) who had been treated for chronic epipharyngitis between June 2021 and September 2021. Epipharyngeal abrasive cells were collected from patients with chronic epipharyngitis before EAT and three months after repeated EAT and were subjected to two-color flow cytometric analyses for CD4 and CD8 expression. The severity of participants' symptoms was monitored using the visual analog scale.
resultsSymptoms of chronic epipharyngitis were significantly abated after three months of repeated EAT (p <0.001). The number of epipharyngeal abrasive CD4(+) T cells in patients with chronic epipharyngitis before EAT, which was significantly higher than that in normal healthy subjects (p <0.01), significantly decreased by the third month of repeated EAT (p = 0.01), alongside symptomatic recovery.
conclusionThese results suggest that epipharyngeal CD4(+) T cells may have a critical role in treating the persistent inflammation of chronic epipharyngitis, and EAT may reduce the number of CD4 cells, which results in symptomatic recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.